Winners and Losers: PTPI, MTTR, and NRXP
Company Name: Petros Pharmaceuticals, Inc.
Ticker: PTPI
Exchange: NASDAQ
Website: https://www.petrospharma.com/
Industry: Health & Wellness
Company Summary:
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health and substance use disorders.
Why is it so Bullish?
Nov. 30, 2021 Petros Pharmaceuticals announces that it has entered into definitive agreements with the company’s largest investor and other existing investors, for the purchase and sale of 3,333,333 shares of Petros Pharmaceuticals’ common stock, at a purchase price of $3.00 per share. The company will sell 2,153,333 shares in a registered direct offering and the remaining 1,180,000 shares will be sold in a private placement. Petros Pharmaceuticals has also agreed to issue the investors unregistered warrants to acquire 2,500,000 shares of common stock at an exercise price of $3.50 per share, exercisable immediately and terminating 5 years after the date of issuance. The closing of the offering is expected to occur on or about December 2, 2021, subject to the satisfaction of customary closing conditions.
1 Day Chart
Technical Summary
Based on the 5 day chart and 1 day chart, I would consider this a bearish trend and would AGAIN, wait for confirmations of a reversal before considering a purchase. NOTE, the 1 month looks interesting but again the short term charts are bearish.
—————————————————————————————————–
Company Name: Matterport, Inc.
Ticker: (MTTR)
Exchange: NASDAQ
Website: https://matterport.com/
Industry: Tech
Company Summary:
Matterport, Inc. (Nasdaq: MTTR) is leading the digital transformation of the built world. Our groundbreaking spatial data platform turns buildings into data to make nearly every space more valuable and accessible. Millions of buildings in more than 150 countries have been transformed into immersive Matterport digital twins to improve every part of the building lifecycle from planning, construction, and operations to documentation, appraisal and marketing.
Why is it so Bullish?
On Nov. 23, 2021 Matterport announced another expansion of Matterport Capture Services™ On-Demand that adds 16 U.S. cities and 20 in Great Britain to its service map, increasing its regional coverage by 55 percent.
5 Day Chart
Technical Summary
Love this stock, it is very bullish and has great news announced today, see below.
Nov. 30, 2021, Matterport introduced Matterport BIM file, a new add-on service that dramatically decreases the time and costs of Building Information Modeling (BIM) for the Architecture, Engineering, and Construction (AEC) industry. Now included with a Matterport subscription, customers can quickly transform a Matterport digital twin captured by a compatible 3D camera into a ready-to-use BIM file at the click of a button. The output is delivered in days, ready to be brought into their BIM application of choice. This new service significantly expedites projects and reduces associated costs by up to 70%, eliminating the traditional manual process that requires considerable time and effort.
—————————————————————————————————–
Company Name: NRx Pharmaceuticals, Inc.
Ticker: (NRXP)
Exchange: NASDAQ
Website: www.nrxpharma.com
Industry: Medical
Company Summary:
NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients. The Company is developing the BriLife® Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense. NRx is additionally developing ZYESAMI® (aviptadil) for patients with COVID-19, and has been granted Fast Track designation by the US Food and Drug Administration (FDA), and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense. The FDA has additionally granted Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support to NRx for NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022.
Why is it so Bullish?
Nov. 29, 2021 NRx Pharmaceuticals announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.
1 Day Chart
Technical Summary:
Another Covid stock, another overbought play that could be a winner but we need confirmation and understanding that it will be volatile.
UPDATE: ISPC Gains 200%, We Called It!
Company Name: iSpecimen
Ticker: ISPC
Exchange: NASDAQ
Website: www.ispecimen.com
Industry Medical
Company Summary:
iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.
Why is it so Bullish?
iSpecimen announced 8 days ago that it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments. In the last ten months, the company has partnered with multiple research and health care organizations on a range of diverse projects requiring a variety of COVID-19 samples, including nasal swabs, saliva, and blood products.
On Nov. 29, 2021 ISPC entered into a definitive securities purchase agreement for a private placement with three accredited investors for the sale of 1,749,999 shares of common stock of iSpecimen together with warrants to purchase 1,312,500 shares of common stock (“Warrants”), which will result in gross proceeds to iSpecimen of approximately $21.0 million, before deducting placement offering expenses.
UPDATE: BELOW is the article written on November 22nd
Small Cap wisely assessed the situation by writing,
“It broke out of the bullish trend at the end of the day, but it could be a head fake. Be careful and make sure to get a solid confirmation before thinking about this purchase.”
WE NAILED IT! The stock went up another 200% after we alerted and it was and always will be about being calculated, not being emotional and reading charts with a technical eye. Always wait for confirmation is the learning lesson!
1 Day Chart
5 Day
Technical Summary
We are in the same boat as last time, we are in a bearish moment on the 1 day but overall still bullish. This stock is volatile right now and be very careful, it is up 300% of late and is overbought. Wait for confirmations and there is a lot of money to be made on the up and coming swings, both positive and negative movements.
3 Momentum Stocks: Avenue Therapeutics (ATXI), Pasithea Therapeutics (KTTA), Biofrontera (BFRI)
There are plenty of stocks that have managed to perform strongly over the course of the past week or so and it is perhaps a good time for investors to take a look at some of those. Here is a look at three of those stocks which have managed to record significant gains in that period.
1 Avenue Therapeutics (NASDAQ:ATXI)
The first one to look into this week is the Avenue Therapeutics Inc stock, which has managed to emerge as one of the biggest gainers in the market over the course of the past week. Yesterday, the stock was in sharp focus among investors and ended the day with gains of as much as 53% as a consequence. The company is mainly involved in the development of intravenous tramadol that is meant for the United States market.
Yesterday, the company got a major boost after Avenue announced that it had been informed by the United States Food and Drug Administration that a meeting is going to take place on February 22, 2022, between the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee.
At the meeting, the New Drug Application submitted by Avenue is going to be discussed by the committees. It is quite clear to see that it is a significant development for the company and hence, the market reacted positively to the news. At this point in time, it might be a good idea to keep the Avenue Therapeutics stock in your watch lists and keep an eye on the developments in the lead-up to February 15 next year.
2 Pasithea Therapeutics (NASDAQ:KTTA)
One of the stocks to have captured the imagination of investors in the past week is that of Pasithea Therapeutics. The stock has had a rollicking run over the course of the past week and managed to clock gains of as much as 80% during the period. There was no news about the company yesterday but the rally actually started in the stock last week after it emerged on November 22 that Pasithea had added its esketamine nasal spray to the range of offerings in the United Kingdom.
The nasal spray is being offered in the United Kingdom through the company’s subsidiary company Pasithea Clinics. The nasal spray in question is meant for treating adults who may be suffering from depression and have not found relief from other forms of treatment.
The company revealed that the spray is not only effective but it is also safe to use. Depression is a worldwide problem and is regarded as one of the major reasons behind long-term disabilities. Many patients suffer from any lack of treatment options and the nasal spray gives them an effective option. The excitement among investors with regard to the product is understandable.
3 Biofrontera (NASDAQ:BFRI)
Last but certainly not least, it is the Biofrontera stock that has grabbed headlines in recent days after having emerged as a major point of focus among investors. Over the course of the past week, the Biofrontera stock has rocketed upwards and managed to clock gains of as much as 175% during the period.
The rally in the Biofrontera stock has come about after a bullish projection from the analyst Jonathan Aschoff of Roth Capital. The analyst started covering the stock last week and set the target price at $20 a share. Aschoff noted that the stock could end up delivering considerable returns primarily due to the sales plans that have been put in place by Biofrontera for the United States market.